| 中文名称 |
罗米地辛, 一种有效的HDAC1和HDAC2抑制剂 |
| 英文名称 |
Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl], cyclic (3→5)-disulfide;Cyclo[(2Z)-2-amino-2-buten |
| CAS识别号 |
128517-07-7 |
| MDL识别号 |
Null,without related properties. |
| EC识别号 |
Null,without related properties. |
| Beilstein |
Null,without related properties. |
| 分子式 |
C24H36N4O6S2 |
| 分子量 |
540.7 |
| 分子结构图 |
 |
| 产品性状 |
经Bellancom Sciences独家专利技术精制而成，符合《中华人民共和国药典》、USP、EP、JP等相关质量标准。 |
| 质量标准 |
Romidepsin, a selective inhibitor of histone deacetylases (HDACs), was approved for the treatment of cutaneous T-cell lymphoma in November 2009 by the U.S. FDA. Romidepsin is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors. Romidepsin strongly down-regulated expression of the immunosuppressive cytokine, interleukin (IL)-10, frequently overexpressed in CTCL, at both the RNA and protein level in CTCL cell lines and at the RNA level in primary CTCL cells. Romidepsin also increased expression of IFNG RNA and decreased expression of IL-2 and IL-4 RNA, although to a lesser extent compared to IL-10. Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. |
| 储存条件 |
-20 °C 冷藏保存，Stored at -20 °C |
| 包装说明 |
Bellancom原装进口,正品保证,Bellancom Chemistry The original. |
| 购买建议 |
Bellancom Chemistry温馨提示：试剂是一种特殊的商品，购买试剂请联系正规企业，防范骗子公司承诺的低价陷阱，我们建议您，在选择供应商时：一要查看“品牌代理授权书”，必要时可向原厂家电话核实；二要索取“正规机打商业企业专用发票”；三 要签订正规试剂购买合同。以上三条是一家正规企业最基本的资质，同时齐备，方可办理汇款，切勿轻信口头承诺，以免上当受骗！ |